Axogen, Inc. — Director's Dealing 2021

Dec 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Axogen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2021-12-27

Reporting Person: Billet Isabelle (Chief Strategy and BD Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-27	Common Stock	M	1150	—	Acquired	14510	Direct
2021-12-27	Common Stock	F	326	$9.74	Disposed	14184	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-27	Restricted Stock Units	$0.0	M	1150	Disposed	2022-12-27	Common Stock (2300.0)	Direct

Footnotes

F1: This reflects the number of restricted stock units that vested on December 27, 2021.

F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F4: All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of theaggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting personupon the vesting date.